Table 1.
Frequency | |||
---|---|---|---|
Age (years) | Median | 62 | |
Range | 27–80 | ||
Gender | M | 149 | 89.22% |
F | 18 | 10.78% | |
Ethnicity | White | 152 | 91.02 |
Hispanic | 13 | 7.78 | |
African–American | 2 | 1.20 | |
Histology | Adeno | 160 | 95.81% |
SCC | 7 | 4.19% | |
Tumor grade | Well‐diff | 4 | 2.40% |
Mod diff | 72 | 43.11% | |
Poorly diff | 91 | 54.49% | |
Baseline EUST Stage | Tx | 8 | 4.79% |
T2 | 19 | 11.38% | |
T3 | 137 | 82.04% | |
T4 | 2 | 1.20% | |
T4b | 1 | 0.60% | |
Baseline EUS N stage | N0 | 60 | 35.93% |
N1 | 102 | 61.08% | |
Nx | 5 | 2.99% | |
Baseline M | M0 | 155 | 92.81% |
M1a | 12 | 7.19% | |
Induction Chemo | Yes | 67 | 40.12 |
No | 100 | 59.88 | |
Type of surgery | Ivor Lewis Esophagectomy | 113 | 67.66 |
Transhiatal Esophagectomy | 18 | 10.77 | |
Transthoracic Esophagectomy | 9 | 5.39 | |
Three‐field Esophagectomy | 13 | 7.78 | |
Minimally Invasive Esophagectomy | 14 | 8.38 | |
Taxanesa | 96 | ||
Platinuma | 86 | ||
Taxane and platinuma | 21 |
EUS denotes, endoscopic ultrasonography.
All patients received a fluoropyrimidine (iv or oral).